Fox Run Management L.L.C. Has $896,000 Stock Position in Insulet Corporation $PODD

Fox Run Management L.L.C. lowered its position in Insulet Corporation (NASDAQ:PODD) by 29.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,853 shares of the medical instruments supplier’s stock after selling 1,211 shares during the period. Fox Run Management L.L.C.’s holdings in Insulet were worth $896,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PODD. Metis Global Partners LLC increased its holdings in shares of Insulet by 6.4% in the second quarter. Metis Global Partners LLC now owns 3,842 shares of the medical instruments supplier’s stock worth $1,207,000 after acquiring an additional 230 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Insulet in the 2nd quarter valued at approximately $67,000. Golden State Wealth Management LLC increased its stake in Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares in the last quarter. Andra AP fonden lifted its stake in Insulet by 167.9% in the second quarter. Andra AP fonden now owns 57,600 shares of the medical instruments supplier’s stock valued at $18,097,000 after buying an additional 36,100 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. lifted its stake in Insulet by 7.6% in the second quarter. Resona Asset Management Co. Ltd. now owns 25,589 shares of the medical instruments supplier’s stock valued at $8,034,000 after buying an additional 1,803 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PODD. Leerink Partners raised their price objective on shares of Insulet from $355.00 to $385.00 and gave the stock an “outperform” rating in a report on Friday. Wells Fargo & Company lifted their price target on Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a research note on Friday. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Barclays increased their price objective on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a report on Wednesday. Finally, Raymond James Financial boosted their target price on Insulet from $360.00 to $366.00 and gave the company an “outperform” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $371.38.

Insulet Price Performance

NASDAQ:PODD opened at $319.82 on Monday. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50. The company has a market cap of $22.51 billion, a P/E ratio of 97.21, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock’s 50-day simple moving average is $325.06 and its 200 day simple moving average is $310.30.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s revenue was up 29.9% compared to the same quarter last year. During the same period last year, the company earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The SEC filing for this sale provides additional information. 0.39% of the stock is currently owned by company insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.